Marker Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Marker Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2017 to Q3 2024.
  • Marker Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 25.2 %, a 44.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 25.2 -20.5 -44.9% Sep 30, 2024
Q2 2024 19.4 -43.2 -69% Jun 30, 2024
Q1 2024 18 -62.9 -77.8% Mar 31, 2024
Q4 2023 31.7 -40.9 -56.4% Dec 31, 2023
Q3 2023 45.7 -20.5 -30.9% Sep 30, 2023
Q2 2023 62.6 +7.99 +14.6% Jun 30, 2023
Q1 2023 80.9 +39.7 +96.6% Mar 31, 2023
Q4 2022 72.6 +39.4 +119% Dec 31, 2022
Q3 2022 66.2 +33.2 +101% Sep 30, 2022
Q2 2022 54.6 +18.8 +52.5% Jun 30, 2022
Q1 2022 41.1 +1.04 +2.6% Mar 31, 2022
Q4 2021 33.2 -7.51 -18.5% Dec 31, 2021
Q3 2021 33 +7.66 +30.3% Sep 30, 2021
Q2 2021 35.8 +21.8 +156% Jun 30, 2021
Q1 2021 40.1 +33.1 +474% Mar 31, 2021
Q4 2020 40.7 +34.2 +534% Dec 31, 2020
Q3 2020 25.3 +19.1 +308% Sep 30, 2020
Q2 2020 14 +5.91 +73.3% Jun 30, 2020
Q1 2020 6.99 -4.39 -38.6% Mar 31, 2020
Q4 2019 6.41 -13 -66.9% Dec 31, 2019
Q3 2019 6.2 -118 -95% Sep 30, 2019
Q2 2019 8.07 -57.1 -87.6% Jun 30, 2019
Q1 2019 11.4 -26.9 -70.3% Mar 31, 2019
Q4 2018 19.4 -11.2 -36.7% Dec 31, 2018
Q3 2018 124 +95.5 +337% Sep 30, 2018
Q2 2018 65.2 Jun 30, 2018
Q1 2018 38.2 Mar 31, 2018
Q4 2017 30.6 Dec 31, 2017
Q3 2017 28.4 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.